Adicet Bio

Historical price data

Adicet Bio is developing first-in-class, allogeneic gamma delta T cell therapies designed to be safer, more readily available, and more effective in solid tumors and autoimmune diseases than current autologous CAR-T options. Its lead candidate, prula-cel (anti-CD20), is in Phase 1 development for B-cell mediated autoimmune diseases, with initial data showing a promising safety profile. The company's strategy hinges on validating its proprietary platform in autoimmune indications to derisk and fund expansion into the larger oncology market, leveraging the innate tissue-homing properties of its cell products.

Proprietary platform for engineering allogeneic gamma delta 1 T cells with CARs or TCRs, leveraging their innate MHC-independent tumor recognition, tissue-homing, and dual innate/adaptive immune functions.

Adicet competes with allogeneic alpha beta CAR-T companies (e.g., Allogene) that require gene editing, and with other gamma delta T cell approaches (e.g., IN8bio). Its key differentiator is a platform leveraging naturally allogeneic, tissue-homing gamma delta 1 T cells, potentially offering a simpler manufacturing and safety profile. In autoimmune diseases, it competes against validated but complex autologous CAR-T therapies.